Key highlights
- Orforglipron achieved primary and key secondary endpoints for weight maintenance vs. placebo at 52 weeks.
- Participants switching from Wegovy to orforglipron maintained all but 0.9 kg of weight loss on average.
- Lilly has submitted orforglipron to the U.S. FDA for obesity treatment approval.
Trial Results
In the ATTAIN-MAINTAIN trial, orforglipron met its primary and all key secondary endpoints for weight maintenance compared to placebo at 52 weeks. Participants who switched from Wegovy to orforglipron maintained nearly all their previous weight loss, with an average regain of only 0.9 kg.
Regulatory Submission
Eli Lilly has submitted orforglipron to the U.S. Food and Drug Administration for approval as a treatment for obesity, marking a significant step in expanding therapeutic options for weight management.
